Research Radartracking 1,138 published studies · 277 human · 6 safety signals · 42 clinical trials · 44 cancer pages · updated Jul 2026Open the Research Map →

Indole-3-Acetic Acid

← All agents

Human-reviewed · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

Evidence at a glanceAnimal onlyReported positive
1 published studies tagged to this agent0 human studies approved & graded (trial, observational, or meta-analysis)
Why this grade?

Animal onlyAnimal studies only — no human data.

Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.

Auto-discovered · not yet curatedindole-3-acetic acid
Educational only, not medical advice. OncoForge makes no claim that Indole-3-Acetic Acid treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Simple Summary

Auto-discovered from 1 recent study; not yet curated.

Research

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
0
Meta-analysis
0
Systematic review
0
Randomized trial
0
Clinical trial
0
Observational
0
Case report
0
Review
0
Preclinical
1
Other
0
1 studies1 animal

Tracking 1 published study of Indole-3-Acetic Acid: 1 in animals.

Reported direction across studies: 1 positive.

No human studies yet — these are preclinical (lab/animal) findings that may not translate to people.

These counts summarize what the studies reported; they are not a measure of whether Indole-3-Acetic Acid works.

Cancers named in these studies

non-small cell lung cancer (1)

All studies

Animal studyReported positivePreclinical onlyTier 2 · animal

Bifidobacterium animalis suppresses non-small cell lung cancer progression and modulates tumor immunity through indole-3-acetic acid

Cell reports · Aug 2025 · mouse models and NSCLC cell lines; gut microbiota comparison in patients with NSCLC and healthy controls

Indole-3-acetic-acidnon-small cell lung cancer

This study looked at gut bacteria and a bacterial metabolite in non-small cell lung cancer. The authors found that Bifidobacterium animalis was lower in patients with NSCLC, and in mouse models and cell lines it was associated with less tumor progression. They identified indole-3-acetic acid as a key metabolite and reported that it affected AHR/METTL3/STAT3 signaling and immune cells in ways linked to reduced tumor growth.

Key findings
  • Bifidobacterium animalis was markedly decreased in patients with NSCLC compared with healthy controls.
  • B. animalis suppressed tumor progression in two NSCLC mouse models and NSCLC cell lines.
  • Indole-3-acetic acid was identified as the pivotal metabolite of B. animalis with anti-NSCLC properties.
  • B. animalis and IAA activated AHR and suppressed METTL3 and STAT3 m6A methylation.
  • B. animalis and IAA reduced M2 macrophage polarization and enhanced CD8+ T cell functions by suppressing IL-6.
Limitations: Preclinical findings dominate the study; the anticancer effects were shown in mouse models and cell lines, not in a human trial.; Human data were observational/comparative microbiome profiling only, so causality cannot be established.; The abstract does not provide sample sizes, doses, or follow-up duration.; The abstract does not report clinical outcomes in patients..

The study links a gut bacterium and its metabolite to NSCLC progression and antitumor immunity in preclinical models.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

What changed recently

The latest additions to Indole-3-Acetic Acid's evidence base, and anything that's been retracted.

Recently added

Cancers where Indole-3-Acetic Acid reported positive results

Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.

Preclinical only: lab / animal (1)
Non-small cell lung cancer1 positive1 animal
Limitations: Preclinical findings dominate the study; the anticancer effects were shown in mouse models and cell lines, not in a human trial.; Human data were observational/comparative microbiome profiling only, so causality cannot be established.; The abstract does not provide sample sizes, doses, or follow-up duration.; The abstract does not report clinical outcomes in patients..
Cited positive studies (1)

Evidence at a glance: Indole-3-Acetic Acid by cancer

A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.

Non-small cell lung cancerAnimal onlyReported positive1 animal

Animal studies only — no human data.

Most authoritative study: Bifidobacterium animalis suppresses non-small cell lung cancer progression and modulates tumor immunity through indole-3-acetic acid

No human studies yet · No numeric effect sizes reported · Based on a single study.

Trials studying Indole-3-Acetic Acid

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar